Author Archives: Joana Carvalho

FDA Names AMP945, Potential IPF Treatment, an Orphan Drug

The U.S. Food and Drug Administration (FDA) has designated AMP945, Amplia Therapeutics’ investigational anti-fibrotic therapy for idiopathic pulmonary fibrosis (IPF), an orphan drug, supporting its development, the company announced. Its decision came about one month after AMP945 also received orphan drug status as a potential pancreatic cancer…

Repeat Hospitalizations in IPF Patients Linked to Poor Survival in Study

Repeat hospitalizations for respiratory problems in people with chronic idiopathic interstitial pneumonia (c-IIP) — a group of chronic lung diseases that also include idiopathic pulmonary fibrosis (IPF) — are associated with poor long-term survival, a study reported. The study, “Characteristics of patients with chronic idiopathic interstitial…

Loss of NEDD4-2 Triggers IPF in Adult Mice, Study Finds

Loss of NEDD4-2 — a protein involved in the regulation of airway hydration and mucus clearance — leads to the onset and development of typical manifestations of idiopathic pulmonary fibrosis (IPF) in adult mice, a study has found. These findings, along with the establishment of a new animal…